Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further re Trading update

18 Oct 2017 07:00

RNS Number : 8763T
Premier Veterinary Group PLC
18 October 2017
 

PREMIER VETERINARY GROUP PLC

("PVG", the "Company" or the "Group")

 

Further re Trading update

 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 

 

 

London, UK, 18 October 2017 - Premier Veterinary Group plc (LSE: PVG) provides the following update on trading, following its previous update on 22 September 2017.

 

Update on US

 

The Board is pleased to announce that it has signed a further cooperation agreement with The Veterinary Cooperative ('TVC'). TVC is a Group Purchasing Organisation with over 3,000 member clinics.

 

The Board has decided to focus the Group's US resources in the mid-west and south-eastern states, where it has its largest presence, until such time that the changes the Group is implementing to improve sign up rates take effect and are sustained. The business will continue to service existing customers in all regions. The decision to focus the Group's resources will be reflected in a lower and slower growing cost base than previously envisaged.

 

Financing

 

As at 30 September 2017, the Group had in excess of £3 million of cash. Additional funds may be required towards the end of the current financial year. The Board is exploring a number of funding options and the directors are confident of being able to raise any additional finance required.

 

Pets on plan

 

The Group's recurring revenue streams are driven by the number of pets that are signed up to Premier Pet Care Plan ("PPCP"), a preventative healthcare programme for pets. The number of revenue generating pets on active plans for the fourth quarter of its 2017 financial year, and in the preceding four quarters was as follows:

 

000's

As at

Sept-16

As at

Dec-16

As at

Mar-17

As at

Jun-17

As at

Sept-17

United Kingdom

121

132

137

145

156

Europe

18

21

22

25

28

US

-

1

2

3

4

 

Total no. of fee generating pets on plan

 

139

 

154

 

161

 

173

 

188

 

The number of revenue generating pets on plan at the end of the financial year represents growth of 35% for the year.

 

In the United Kingdom, the number of pets on PPCP has grown by 29% on last year. The UK PPCP business is well established, cash generative and continues to see opportunities for growth from its existing customer base and new customer opportunities.

 

In Europe, the number of pets on PPCP at 30 September 2017 has grown by 56% on last year. Our most significant territory in Europe is the Netherlands. PPCP is branded as Huisdieren Zorg Plan ("HZP") in the Netherlands. The number of pets on HZP has grown by 46% in the last year to 24,000 pets on PPCP at 30 September 2017. HZP is expected to become profitable in the financial year ending 30 September 2018.

 

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Will Evans, Chief Financial Officer

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary, Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare programme for pets branded "Premier Pet Care Plan" ("PPCP"). In the US, where veterinary practices are known as veterinary hospitals, PPCP is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

PPCP is a structured, preventative healthcare programme for cats, dogs and rabbits and is available only through veterinary practices/hospitals. The programme is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

 

PPCP uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed 

more quickly and not given a chance to advance. What truly sets PPCP apart is its unique approach of offering an end-to-end solution and support to the practice/hospital, which has been proven to work extremely well. PVA works alongside practices/hospitals to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice/hospital performance.

 

 

For further details:

http://www.premiervetgroup.co.uk/

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward- looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors readers are cautioned not to rely on any forward-looking statement.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFFMFWWFWSESS
Date   Source Headline
6th Sep 20134:40 pmRNSSecond Price Monitoring Extn
6th Sep 20134:35 pmRNSPrice Monitoring Extension
6th Sep 201312:54 pmRNSHolding(s) in Company
4th Sep 20134:40 pmRNSSecond Price Monitoring Extn
4th Sep 20134:35 pmRNSPrice Monitoring Extension
2nd Sep 201312:00 pmRNSHolding(s) in Company
29th Aug 20134:41 pmRNSSecond Price Monitoring Extn
29th Aug 20134:35 pmRNSPrice Monitoring Extension
29th Aug 20139:00 amRNSHalf Yearly Report
16th Aug 20134:40 pmRNSSecond Price Monitoring Extn
16th Aug 20134:35 pmRNSPrice Monitoring Extension
15th Aug 20135:32 pmRNSHolding(s) in Company
14th Aug 20134:56 pmRNSHolding(s) in Company
30th Jul 20134:40 pmRNSSecond Price Monitoring Extn
30th Jul 20134:35 pmRNSPrice Monitoring Extension
23rd Jul 20133:44 pmRNSHolding(s) in Company
9th Jul 20132:00 pmRNSCompany Update
8th Jul 20134:40 pmRNSSecond Price Monitoring Extn
8th Jul 20134:35 pmRNSPrice Monitoring Extension
5th Jul 201310:48 amRNSHolding(s) in Company
5th Jul 20137:00 amRNSCompany Update
27th Jun 20134:40 pmRNSSecond Price Monitoring Extn
27th Jun 20134:35 pmRNSPrice Monitoring Extension
25th Jun 20132:05 pmRNSResults of Annual General Meeting
14th Jun 20134:40 pmRNSSecond Price Monitoring Extn
14th Jun 20134:35 pmRNSPrice Monitoring Extension
4th Jun 20132:48 pmRNSBlocklisting Six Monthly Return
24th May 20134:40 pmRNSSecond Price Monitoring Extn
24th May 20134:35 pmRNSPrice Monitoring Extension
17th May 20137:00 amRNSInterim Management Statement
16th May 20131:20 pmRNSHolding(s) in Company
8th May 20136:09 pmRNSHolding(s) in Company
8th May 20135:47 pmRNSHolding(s) in Company
2nd May 20131:45 pmRNSHolding(s) in Company
1st May 20134:35 pmRNSPrice Monitoring Extension
30th Apr 20137:00 amRNSFinal Results
26th Apr 20134:50 pmRNSHolding(s) in Company
24th Apr 20133:47 pmRNSHolding(s) in Company
26th Mar 20134:40 pmRNSSecond Price Monitoring Extn
26th Mar 20134:35 pmRNSPrice Monitoring Extension
22nd Mar 201311:50 amRNSHolding(s) in Company
20th Mar 20131:15 pmRNSHolding(s) in Company
19th Mar 201311:34 amRNSForm 8.3 - Ark Therapeutics
19th Mar 20139:47 amRNSHolding(s) in Company
18th Mar 20131:54 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Mar 201312:01 pmRNSTermination of Offer Period and Rule 10.8 Waiver
7th Mar 20134:22 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 20133:04 pmRNSForm 8.3 - [Ark Therapeutics Group]
6th Mar 201310:02 amRNSForm 8.3 - Ark Therapeutics Group Plc
1st Mar 201311:49 amRNSForm 8.3 - Ark Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.